M6PR Inhibitors
2 drugsAbout M6PR
M6PR (Mannose-6-Phosphate Receptor) is crucial for trafficking lysosomal enzymes within cells, ensuring proper lysosome function in waste breakdown and recycling.
M6PR's role in lysosomal function makes it a therapeutic target, particularly where lysosomal dysfunction is implicated in disease; there is currently no genetic evidence linking M6PR to specific diseases.
Two FDA-approved biologic drugs, LUMIZYME and MYOZYME (both Sanofi), target M6PR for lysosomal storage disorders, with approvals spanning from 2006 to 2010.
Top M6PR Drugs
Sanofi is the only company with approved drugs targeting M6PR.
High market concentration suggests significant barriers to entry for new competitors.
M6PR Drug Modality Landscape
Modalities
Routes of Administration
M6PR requires biologic approaches (enzyme), likely due to its structure or location.
The lack of small molecule drugs targeting M6PR represents a potential whitespace opportunity.
M6PR Clinical Trials 12 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on M6PR. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 | - |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 9 | 6 | 3 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M6PR Drug Approval Timeline (2006 - 2010)
The approval timeline for M6PR-targeting drugs spans from 2006 to 2010.
The limited approval window suggests potential saturation or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on M6PR. A trial counts if an approved drug acting on M6PR is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.